Skip to content
Surf Wiki
Save to docs
general/manufacturing-companies-based-in-espoo

From Surf Wiki (app.surf) — the open knowledge base

Orion Corporation (Finnish company)

Finnish pharmaceutical company


Finnish pharmaceutical company

FieldValue
nameOrion Corporation
native_nameOrion Oyj
native_name_langfi
logoOrion pharma logo (2025-).svg
logo_size250px
typeJulkinen osakeyhtiö
traded_as,
foundation
locationEspoo, Finland
key_peopleLiisa Hurme (President and CEO), Mikael Silvennoinen (Chairman)
industryPharmaceutical industry
productsPharmaceuticals and active pharmaceutical ingredients
revenue€1.041 billion (2021)
operating_income€243.3 million (2021)
net_income€193.8 million (2021)
assets€1.114 billion (2021)
equity€747.9 million (2021)
num_employees3,364 (2021)
homepage
footnotes
Note

the pharmaceutical company

Orion Corporation (), founded in 1917 and headquartered at Espoo, Finland, is a globally operating Finnish company which develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients for global markets. All of the company's manufacturing sites and the majority of its R&D units are in Finland.

Orion's class A and B shares are listed on the Helsinki Stock Exchange.

History

Orion was founded on September 21, 1917 by pharmacists Onni Turpeinen, Eemil Tuurala and Wikki Valkama. Before founding Orion, they worked in a pharmaceutical-chemical factory called Medica. The first premises of the new company were found in a courtyard building in Helsinki's Kruununhaka, Mariankatu 24, i.e. Asunto Oy Mars star. Among the first products of the apothecary were Ballistol gun oil and dulcine. Pediatrician Arvo Ylppö played a significant role starting in the 1920s.

Orion's diagnostics business was previously concentrated in the Orion Diagnostica profit unit, which was sold to a private equity investor in April 2018. The diagnostics business included the development, manufacture and marketing of diagnostic tests and hygiene tests. Orion Diagnostica changed its name in November 2019 and is now Aidian.

Notable products

The following are Orion's top-selling product lines as of March 2021.

Trade nameGeneric nameIndication
Stalevo,Comtess/ ComtanEntacaponeParkinson's disease
Easyhalermulti-dose dry-powder inhaler for asthma.asthma, COPD
SimdaxLevosimendanacute heart failure
dexdordexmedetomidineintensive care sedative
Dexdomitordexmedetomidineanimal sedative
Domitormedetomidineanimal sedative
Domosedandetomidineanimal sedative
Antisedanatipamezolereversing agent
NubeqaDarolutamidenon-metastatic castration-resistant prostate cancer
SolometMethylprednisoloneinflammation
Divina seriesEstradiol valerate and Medroxyprogesterone acetatehormone replacement against menopausal symptoms
FarestonToremifeneSelective estrogen receptor modulator
Buranaibuprofeninflammatory pain
Marevanwarfarinanticoagulant

References

References

  1. "Orion Group - Financial Statement Release 2021".
  2. "About Orion".
  3. "Orionin virstanpylväitä 1910-luvulla".
  4. "Orionin vahva mies {{!}} Arvo Ylppö".
  5. Moran, Mark. (2018-05-18). "''AJP'' Board Member Responds to ''NYT'' Story On Antidepressant Withdrawal". Psychiatric News.
  6. "Orion Diagnostica on nyt Aidian".
  7. "Orion Result Presentation 1−3/2021".
  8. "Orion Oyj". Finnish Patent and Registration Office and Finnish Tax Administration.
  9. (22 March 2017). "Yhtiöjärjestys". Orion Oyj.
Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

Want to explore this topic further?

Ask Mako anything about Orion Corporation (Finnish company) — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report